



## Announcement Summary

---

**Entity name**

MELODIOL GLOBAL HEALTH LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

7/12/2023

**The Proposed issue is:**

A placement or other type of issue

**Total number of +securities proposed to be issued for a placement or other type of issue**

ASX +security code	+Security description	Maximum Number of +securities to be issued
ME1	ORDINARY FULLY PAID	2,141,914,080

**Proposed +issue date**

15/1/2024

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of +Entity

MELODIOL GLOBAL HEALTH LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

### 1.2 Registered Number Type

ACN

### Registration Number

609406911

### 1.3 ASX issuer code

ME1

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

7/12/2023

### 1.6 The Proposed issue is:

A placement or other type of issue



## Part 7 - Details of proposed placement or other issue

## Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?** Yes

## 7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	15/1/2024	<input checked="" type="checkbox"/> Estimated	No

**Comments**

Shareholder approval is required to be obtained by 15 January 2024

## Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

 Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

 No

## Details of +securities proposed to be issued

**ASX +security code and description**

ME1 : ORDINARY FULLY PAID

**Number of +securities proposed to be issued**

2,141,914,080

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

 No



**Please describe the consideration being provided for the +securities**

Principal, Interest and modification fees payable in relation to the La Plata secured note. Refer to ASX announcement dated 7 December 2023 for further information.

**Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities**

4,283,828.000000

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

---

Part 7C - Timetable

**7C.1 Proposed +issue date**

15/1/2024

---

Part 7D - Listing Rule requirements

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

Yes

**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

15/1/2024

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

---

Part 7E - Fees and expenses

**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

**7E.2 Is the proposed issue to be underwritten?**



No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

To be issued in lieu of cash payments for principal, interest, and modification fees due to La Plata

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

Shares are proposed to be issued for:

- Up to 764,396,093 Shares- Oct Nov Dec '23, Jan & Feb '24 interest
- Up to 251,199,996 Shares- Oct & Nov '23 principal
- Up to 565,199,991 Shares- Dec '23, Jan & Feb '24 principal
- Up to 502,400,000 Shares- modification fee
- Up to 58,718,000 Shares- legal fees

The above are estimates only, based on a floor price of \$0.001 per Share and an exchange rate of US\$1.00 = A\$1.57. Actual number of Shares to be issued will be determined based on the exchange rate and the Company's closing Share price on the trading day immediately prior to issuance, at a ratio of 2.0 times the interest due, and a floor price of A\$0.001 per Share.

Refer to ASX announcement dated 7 December 2023 for further information.

**7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)